Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden GGVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Lawrence Wickerham D, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL.

J Natl Cancer Inst. 2019 Mar 19. pii: djz032. doi: 10.1093/jnci/djz032. [Epub ahead of print]


Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.

Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA.

Clin Cancer Res. 2019 Feb 26. doi: 10.1158/1078-0432.CCR-18-2206. [Epub ahead of print]


Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA.

J Clin Oncol. 2019 Jan 20;37(3):178-189. doi: 10.1200/JCO.18.01624. Epub 2018 Dec 6.


Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.

Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL.

PLoS One. 2018 Aug 17;13(8):e0200836. doi: 10.1371/journal.pone.0200836. eCollection 2018.


Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).

Kim SR, Song N, Yothers G, Gavin PG, Allegra CJ, Paik S, Pogue-Geile KL.

Br J Cancer. 2018 Mar 6;118(5):629-633. doi: 10.1038/bjc.2017.448. Epub 2017 Dec 14.


Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors-Reply.

Kim SR, Gavin PG, Pogue-Geile K.

JAMA Oncol. 2018 Jan 1;4(1):132-133. doi: 10.1001/jamaoncol.2017.2813. No abstract available.


Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.

JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.


Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.

Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.

JAMA Oncol. 2017 Mar 1;3(3):335-341. doi: 10.1001/jamaoncol.2016.4884.


Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S.

JAMA Oncol. 2016 Sep 1;2(9):1162-9. doi: 10.1001/jamaoncol.2016.2314.


Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.

Gavin PG, Song N, Kim SR, Pogue-Geile KL, Paik S.

J Clin Oncol. 2015 Nov 1;33(31):3671-2. doi: 10.1200/JCO.2015.61.9650. Epub 2015 Aug 17. No abstract available.


Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Clin Oncol. 2015 Apr 20;33(12):1340-7. doi: 10.1200/JCO.2014.56.2439. Epub 2015 Jan 5.


Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.


Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. doi: 10.1093/jnci/djt140.


Colon cancer mutation: prognosis/prediction--response.

Gavin PG, Paik S, Yothers G, Pogue-Geile KL.

Clin Cancer Res. 2013 Mar 1;19(5):1301. doi: 10.1158/1078-0432.CCR-13-0020. Epub 2013 Feb 8. No abstract available.


Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL.

Clin Cancer Res. 2012 Dec 1;18(23):6531-41. doi: 10.1158/1078-0432.CCR-12-0605. Epub 2012 Oct 8.


Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.


A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.

Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL.

BMC Cancer. 2010 Mar 16;10:101. doi: 10.1186/1471-2407-10-101.


Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism.

Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC, Brentnall TA.

PLoS Med. 2006 Dec;3(12):e516.


Molecular overlap of fly circadian rhythms and human pancreatic cancer.

Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC.

Cancer Lett. 2006 Nov 8;243(1):55-7. Epub 2006 Jan 31. Review.


Pancreatitis as a risk for pancreatic cancer.

Whitcomb DC, Pogue-Geile K.

Gastroenterol Clin North Am. 2002 Jun;31(2):663-78. Review.


A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34.

Eberle MA, Pfützer R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, Duerr RH, Kruglyak L, Whitcomb DC, Brentnall TA.

Am J Hum Genet. 2002 Apr;70(4):1044-8. Epub 2002 Feb 27.


Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.

Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH.

Cancer Res. 2001 Mar 15;61(6):2625-31.


A CF modifier means meconium in mouse and man.

Whitcomb DC, Pogue-Geile KL.

Gastroenterology. 2000 Jul;119(1):268-9. No abstract available.


Activation of the nitric oxide synthase 2 pathway in the response of bone marrow stromal cells to high doses of ionizing radiation.

Gorbunov NV, Pogue-Geile KL, Epperly MW, Bigbee WL, Draviam R, Day BW, Wald N, Watkins SC, Greenberger JS.

Radiat Res. 2000 Jul;154(1):73-86.


Stromal cell involvement in leukemogenesis and carcinogenesis.

Greenberger JS, Epperly MW, Zeevi A, Brunson KW, Goltry KL, Pogue-Geile KL, Bray J, Berry L.

In Vivo. 1996 Jan-Feb;10(1):1-17.


Role of bone marrow stromal cells in irradiation leukemogenesis.

Greenberger JS, Epperly MW, Jahroudi N, Pogue-Geile KL, Berry L, Bray J, Goltry KL.

Acta Haematol. 1996;96(1):1-15.


Cloning and expression of unique murine macrophage colony-stimulating factor transcripts.

Pogue-Geile K, Sakakeeny MA, Panza JL, Sell SL, Greenberger JS.

Blood. 1995 Jun 15;85(12):3478-86.


Gene structure and expression in colorectal cancer.

Pipas JM, Pogue-Geile K, Finley GG, Cartwright CA, Meiesler AI.

Adv Exp Med Biol. 1993;330:67-75. Review.


Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein.

Pogue-Geile K, Geiser JR, Shu M, Miller C, Wool IG, Meisler AI, Pipas JM.

Mol Cell Biol. 1991 Aug;11(8):3842-9.


Fine mapping of mutations in the fusion-inducing MP strain of herpes simplex virus type 1.

Pogue-Geile KL, Lee GT, Shapira SK, Spear PG.

Virology. 1984 Jul 15;136(1):100-9.


Involvement of directly repeated sequences in the generation of deletions of the avian sarcoma virus src gene.

Omer CA, Pogue-Geile K, Guntaka R, Staskus KA, Faras AJ.

J Virol. 1983 Aug;47(2):380-2.


Expression of herpes simplex virus glycoprotein C from a DNA fragment inserted into the thymidine kinase gene of this virus.

Lee GT, Pogue-Geile KL, Pereira L, Spear PG.

Proc Natl Acad Sci U S A. 1982 Nov;79(21):6612-6.


Nucleotide sequence analysis of in vivo recombinants between bacteriophage lambda DNA and pBR322.

King SR, Krolewski MA, Marvo SL, Lipson PJ, Pogue-Geile KL, Chung JH, Jaskunas SR.

Mol Gen Genet. 1982;186(4):548-57.


Identification of a second tetracycline-inducible polypeptide encoded by Tn10.

Zupancic TJ, King SR, Pogue-Geile KL, Jaskunas SR.

J Bacteriol. 1980 Oct;144(1):346-55.


Recombination between bacteriophage lambda and plasmid pBR322 in Escherichia coli.

Pogue-Geile KL, DasSarma S, King SR, Jaskunas SR.

J Bacteriol. 1980 Jun;142(3):992-1003.

Supplemental Content

Loading ...
Support Center